Guard Therapeutics International Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Guard Therapeutics InternationalDer Gewinn des Unternehmens wird voraussichtlich um 8.1% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 165.5% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich wachsen um 0.3% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 164.6% betragen.

Wichtige Informationen

-8.1%

Wachstumsrate der Gewinne

0.3%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	45.7%
Wachstumsrate der Einnahmen	165.5%
Zukünftige Eigenkapitalrendite	164.6%
Analystenabdeckung	Low
Zuletzt aktualisiert	18 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

We're Keeping An Eye On Guard Therapeutics International's (STO:GUARD) Cash Burn Rate

Nov 19

Companies Like Guard Therapeutics International (STO:GUARD) Could Be Quite Risky

Apr 18

Guard Therapeutics International (STO:GUARD) Will Have To Spend Its Cash Wisely

Jan 04

Here's Why Guard Therapeutics International (STO:GUARD) Must Use Its Cash Wisely

Sep 20

Guard Therapeutics International (STO:GUARD) Is In A Good Position To Deliver On Growth Plans

Apr 06

We're Keeping An Eye On Guard Therapeutics International's (STO:GUARD) Cash Burn Rate

Sep 09

Here's Why We're A Bit Worried About Guard Therapeutics International's (STO:GUARD) Cash Burn Situation

Feb 19

We're Not Very Worried About Guard Therapeutics International's (STO:GUARD) Cash Burn Rate

Aug 17

Companies Like Guard Therapeutics International (STO:GUARD) Are In A Position To Invest In Growth

Apr 19

Here's Why We're Watching Guard Therapeutics International's (STO:GUARD) Cash Burn Situation

Jan 04

Gewinn- und Umsatzwachstumsprognosen

OM:GUARD - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (SEK Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	312	N/A	N/A	N/A	1
12/31/2025	N/A	-99	-99	-99	1
12/31/2024	N/A	-96	-99	-99	1
9/30/2024	N/A	-87	-92	-92	N/A
6/30/2024	N/A	-79	-81	-81	N/A
3/31/2024	N/A	-88	-101	-101	N/A
12/31/2023	N/A	-113	-116	-116	N/A
9/30/2023	N/A	-137	-133	-133	N/A
6/30/2023	N/A	-146	-138	-138	N/A
3/31/2023	N/A	-134	-120	-120	N/A
12/31/2022	N/A	-113	-102	-102	N/A
9/30/2022	N/A	-95	-93	-93	N/A
6/30/2022	N/A	-97	-93	-93	N/A
3/31/2022	N/A	-88	-86	-86	N/A
12/31/2021	N/A	-82	-78	-78	N/A
9/30/2021	N/A	-69	-63	-63	N/A
6/30/2021	N/A	-47	-43	-43	N/A
3/31/2021	N/A	-44	-40	-40	N/A
12/31/2020	N/A	-40	-38	-38	N/A
9/30/2020	N/A	-43	-36	-37	N/A
6/30/2020	N/A	-39	-38	-38	N/A
3/31/2020	N/A	-41	-39	-39	N/A
12/31/2019	N/A	-45	-60	-60	N/A
9/30/2019	N/A	-73	-65	-66	N/A
6/30/2019	N/A	-82	-65	-66	N/A
3/31/2019	N/A	-86	-78	-78	N/A
12/31/2018	N/A	-87	-58	-58	N/A
9/30/2018	N/A	-61	-59	-58	N/A
6/30/2018	N/A	-63	N/A	-59	N/A
3/31/2018	N/A	-67	N/A	-70	N/A
12/31/2017	N/A	-68	N/A	-66	N/A
9/30/2017	N/A	-72	N/A	-72	N/A
6/30/2017	N/A	-68	N/A	-68	N/A
3/31/2017	N/A	-61	N/A	-43	N/A
12/31/2016	N/A	-52	N/A	-47	N/A
9/30/2016	N/A	-43	N/A	-35	N/A
6/30/2016	N/A	-35	N/A	-34	N/A
3/31/2016	N/A	-32	N/A	-35	N/A
12/31/2015	N/A	-30	N/A	-27	N/A
9/30/2015	N/A	-23	N/A	-24	N/A
6/30/2015	0	-20	N/A	-18	N/A
3/31/2015	0	-15	N/A	-14	N/A
12/31/2014	0	-14	N/A	-15	N/A
9/30/2014	2	-12	N/A	-10	N/A
6/30/2014	5	-9	N/A	-8	N/A
3/31/2014	7	-7	N/A	-4	N/A
12/31/2013	8	-5	N/A	-3	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: GUARD wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: GUARD wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: GUARD wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: GUARD wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Hohe Wachstumseinnahmen: GUARD wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: GUARDDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich sehr hoch sein (164.6%).

Guard Therapeutics International Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

No longer forecast to breakeven

Price target decreased by 36% to kr1.61

No longer forecast to breakeven

Price target decreased by 36% to kr1.61

No longer forecast to breakeven

No longer forecast to breakeven

Recent updates

We're Keeping An Eye On Guard Therapeutics International's (STO:GUARD) Cash Burn Rate

New major risk - Financial position

Guard Therapeutics Announces First Patient in Europe Dosed in the Clinical Phase 2b POINTER Study

Guard Therapeutics International AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 7.185811 million.

First Patient Dosed in Guard Therapeutics' Phase 2B Study POINTER

New major risk - Financial position

Guard Therapeutics Receives Regulatory EU Approvals to Include Patients in its Phase 2b Study POInter

New minor risk - Shareholder dilution

New major risk - Share price stability

New major risk - Revenue and earnings growth

Companies Like Guard Therapeutics International (STO:GUARD) Could Be Quite Risky

No longer forecast to breakeven

New major risk - Share price stability

New major risk - Financial position

Guard Therapeutics International (STO:GUARD) Will Have To Spend Its Cash Wisely

New major risk - Revenue and earnings growth

Guard Therapeutics Reports Robust Efficacy of RMC-035 in Phase 2 (Akita) and Advances Clinical Development Program

Here's Why Guard Therapeutics International (STO:GUARD) Must Use Its Cash Wisely

New minor risk - Financial position

New major risk - Revenue and earnings growth

Guard Therapeutics International AB Announces Completion of Clinical Phase 2 Study AKITA

Guard Therapeutics Announces the Full Results from the Phase 1B Clinical Study of the Investigational Drug RMC-035 in Patients Undergoing Kidney Transplantation

Price target decreased by 36% to kr1.61

No longer forecast to breakeven

Price target decreased by 36% to kr1.61

Guard Therapeutics International (STO:GUARD) Is In A Good Position To Deliver On Growth Plans

No longer forecast to breakeven

Guard Therapeutics Announces First Patient in US Dosed with Study Drug in the Ongoing Global Phase 2 Clinical Trial AKITA

Guard Therapeutics International AB (Publ) Announces 134 of the Planned 268 Patients Have Been Dosed in the Global Randomized, Double-Blinded and Placebo-Controlled Phase 2 Clinical Trial

No longer forecast to breakeven

Guard Therapeutics International AB (publ) Receives FDA Fast Track Designation for RMC-035

Guard Therapeutics International AB (publ) Receives IND Approval from the FDA for RMC-035

We're Keeping An Eye On Guard Therapeutics International's (STO:GUARD) Cash Burn Rate

Guard Therapeutics Announces That the First Patient Has Been Dosed in A Phase 1b Clinical Trial of the Investigational Drug RMC-035 (ROSgard) in Kidney Transplantation

Guard Therapeutics Announces That the First Patient Has Been Dosed in A Phase 1b Clinical Trial of the Investigational Drug RMC-035 (ROSgard) in Kidney Transplantation

Guard Therapeutics Receives Approval from the Swedish Medical Products Agency to Conduct A Clinical Study of RMC-035 in Kidney Transplantation

Price target decreased to kr2.15

High number of new and inexperienced directors

Guard Therapeutics International AB (publ) Appoints Torbjörn Larsson as Head of CMC (Chemistry, Manufacturing and Controls), Effective 1 May 2022

Guard Therapeutics International AB (publ) Provides In-Depth Information on Phase 2 Clinical Trial

Guard Therapeutics Announces First Patient Has Been Dosed in Guard Therapeutics' Phase 2 Clinical Trial of ROSgard

Forecast to breakeven in 2024

Here's Why We're A Bit Worried About Guard Therapeutics International's (STO:GUARD) Cash Burn Situation

Chief Executive Officer recently bought kr1.6m worth of stock

Guard Therapeutics Receives Approval to Expand the Global Phase 2 Study of Rosgard to Canada

Guard Therapeutics’ Application to Conduct a Phase 2 Clinical Trial of ROSgard is Approved by the German Medicines Regulator

Chief Executive Officer recently bought kr300k worth of stock

Guard Therapeutics International AB (Publ) Reports Positive Results from Preclinical Studies

We're Not Very Worried About Guard Therapeutics International's (STO:GUARD) Cash Burn Rate

Companies Like Guard Therapeutics International (STO:GUARD) Are In A Position To Invest In Growth

Guard Therapeutics appoints Sara Thuresson as Head of Clinical Operations

New 90-day high: kr1.50

Here's Why We're Watching Guard Therapeutics International's (STO:GUARD) Cash Burn Situation

Guard Therapeutics International AB (Publ) Completes Pre-IND meeting with FDA

Guard Therapeutics Appoints Ann-Kristin Myde as Head of Global Project Management, Effective 1 April 2021

New 90-day low: kr1.22

New 90-day low: kr1.23

Guard Therapeutics Reports Positive Top-Line Results from Phase 1 Study of Rosgard in Individuals with Renal Impairment

New 90-day high - kr1.60

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken